Cargando…

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada

This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia. We conducted a statistical analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) and the Canad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Thibault B., Schleret, Thomas R., Reilly, Brian M., Chen, Winston Yuchen, Abagyan, Ruben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671709/ https://www.ncbi.nlm.nih.gov/pubmed/26642212 http://dx.doi.org/10.1371/journal.pone.0144337

Ejemplares similares

The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada
por: Huang, Allen R, et al.
Publicado: (2015)

Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
por: Kobayashi, Shotaro, et al.
Publicado: (2023)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study
por: Campillo, Jérémy T., et al.
Publicado: (2021)

Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia
por: Hoffmann, Falk, et al.
Publicado: (2011)

Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary
por: Balázs, Nóra, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

OUTCOMES OF DISCONTINUING CHOLINESTERASE INHIBITORS IN NURSING HOME RESIDENTS WITH SEVERE DEMENTIA
por: Niznik, Joshua D, et al.
Publicado: (2019)

Potential and Pitfalls of Pharmacovigilance Databases in Oncology
por: Schlam, Ilana, et al.
Publicado: (2023)

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
por: Zheng, Yi, et al.
Publicado: (2023)

Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices
por: Hans, Mohit, et al.
Publicado: (2018)

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
por: Meng, Yan-Hong, et al.
Publicado: (2019)

Safety of Anthroposophic Medicinal Products: An Analysis of Adverse Drug Reactions from German Pharmacovigilance Databases
por: Jong, Miek C., et al.
Publicado: (2021)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Adverse Drug Reactions and Potentially Inappropriate Medication in Older Patients: Analysis of the Portuguese Pharmacovigilance Database
por: Gomes, Daniel, et al.
Publicado: (2022)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Quality of Spontaneous Reports of Adverse Drug Reactions Sent to a Regional Pharmacovigilance Unit
por: Salvador, Mário Rui, et al.
Publicado: (2022)

COVID-19 Vaccines Adverse Reactions Reported to the Pharmacovigilance Unit of Beira Interior in Portugal
por: Amaro, Carina, et al.
Publicado: (2022)

Persistence of Cholinesterase Inhibitor Treatment in Dementia: Insights from a Naturalistic Study
por: Olazarán, Javier, et al.
Publicado: (2013)

Concomitant Cholinesterase Inhibitor and Anticholinergic Drug Use Among Older Adults With Dementia
por: Carter, Elizabeth, et al.
Publicado: (2020)

Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation
por: Ozcan, Gulnihal, et al.
Publicado: (2016)

A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases
por: Brabete, Andreea C., et al.
Publicado: (2022)

Signal Detection of Adverse Drug Reactions of Cephalosporins Using Data from a National Pharmacovigilance Database
por: Choi, Jung-Yoon, et al.
Publicado: (2021)

Adverse effects of gender‐affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database
por: Yelehe, Melissa, et al.
Publicado: (2022)

Reports of Symptoms Associated with Supraventricular Arrhythmias as a Serious Adverse Drug Reaction in the Spanish Pharmacovigilance Database
por: Pueyo-Val, Javier, et al.
Publicado: (2023)

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis
por: Caro, Jaime, et al.
Publicado: (2003)

Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
por: Joulfayan, Haroutyun, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program
por: Piovesana, Magda Cristina Flaitt Sanches, et al.
Publicado: (2012)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
por: Ortner, Marion, et al.
Publicado: (2020)

Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2021)

Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database
por: Campillo, Jeremy T., et al.
Publicado: (2022)

Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias
por: Fallon, Sean James, et al.
Publicado: (2023)

Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing
por: Schmider, Juergen, et al.
Publicado: (2018)

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
por: Wu, Bin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p6d6090qs2kleqm4cafn2iko6i